Nebivolol Normon (Nebivolol Hydrochloride)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force. At the same time it enhances endothelial nitric‑oxide production, causing peripheral vasodilation. This combined effect lowers arterial pressure while preserving cardiac output.

The dose of nebivolol is individualized by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety of nebivolol in pregnancy and lactation has not been established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Nebivolol Normon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nebivolol is a highly selective β1‑blocker that also stimulates nitric‑oxide release, offering vasodilatory benefits not seen with many older non‑selective beta‑blockers. This profile can result in fewer metabolic side effects and better tolerability in some patients, while still providing effective blood‑pressure control.

Store Nebivolol Normon at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain product stability.

Nebivolol Normon is taken orally, usually once daily with or without food, as directed by the prescribing healthcare professional. The tablet should be swallowed whole with a glass of water.

Serious risks include severe bradycardia, symptomatic hypotension, heart block (especially in patients with pre‑existing conduction disorders), and bronchospasm in individuals with reactive airway disease. Patients should be monitored for these events, particularly during dose initiation or adjustment.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or severe asthma/COPD that is not well controlled.